Delegates

Airport Authority Hong Kong is a statutory body responsible for the operation and development of Hong Kong International Airport (HKIA).

As a leading international aviation hub, HKIA connects with over 220 destinations worldwide and is served by some 120 airlines. With its strategic geographical location, flights from HKIA can reach half of the world’s population within five hours. HKIA has for many years been the world’s leading air cargo hub. It was the world’s busiest cargo airport in 2022 according to the Airports Council International, handling 4.2 million tonnes of cargo. Before the pandemic, HKIA handled over 70 million passengers annually.

HKIA is taking forward an array of developments under the Airport City blueprint, which comprises office, hotel, retail, dining, entertainment, conference and exhibition facilities in the vicinity of the airport. The Airport City aspires to become a world-class destination for locals and visitors from around the world.

Invest Hong Kong (InvestHK) is the Hong Kong Special Administrative Region (HKSAR) Government Department responsible for attracting Foreign Direct Investment and supporting overseas and Mainland businesses to set up or expand in Hong Kong.

InvestHK has industry specialists in a range of priority sectors including: Business & Professional Services, Consumer Products, Creative Industries, Family Offices, Financial Services & Financial Technology, Innovation & Technology, Startups & Entrepreneurs, Tourism & Hospitality, and Transport & Industrial plus a network of staff and representatives based in 34 key business cities worldwide covering its target markets.

Partners with clients on a long-term basis, InvestHK team is available to help at any stage of their business development in Hong Kong. It provides free advice and customised services to help businesses succeed in Hong Kong's vibrant economy.

The French Chamber of Commerce and Industry in Hong Kong has been serving the interests of the French and international business community in Hong Kong for over 35 years.

We help companies set up and expand in Hong Kong while driving closer engagement between the French and local business communities.

Atelier Pacific is a leading multidisciplinary creative studio with nearly three decades of experience, serving clients across Asia, Europe, and North America. They prioritize creative design and technical proficiency, partnering with clients to create bespoke systems that maximize the aesthetic and functional possibilities of each space. Their portfolio includes critically acclaimed projects in cultural, commercial, and civic spaces, as well as urban and transport master planning. Atelier Pacific's integrated design process and open workshop culture draw upon a diverse skill set and global visual perspectives, resulting in optimal solutions and distinctive designs for clients. Their meticulous attention to detail is evident in every project they undertake.

AaaM Architects is an international award-winning design and research studio founded in 2015 in Hong Kong. “AaaM” is abbreviated from “Architecture as a Medium”. The studio believes in architecture’s power as a medium with which all walks of life can engage and interact in everyday life, and strive to create designs that positively impact all aspects of life. Their focus includes social design, place making and urban revitalization, and they adopt a bottom-up approach to create social places with identity and belongings.The studio has gained international recognition with a number of awards including German Iconic design Award, Paris DNA Award, Japan Good Design Award - Best 100, etc.

Business mission AAA is a multidisciplinary design firm rooted in architecture committed to making a difference through design. AAA's mission is to develop captivating projects—innovative, adaptable environments and concepts that benefit their users and community.

Instead of adhering to a predetermined aesthetic, AAA cultivates a wide range of styles and competencies to produce intelligent and original design solutions that change to meet the demands of each project.

We strive to cater to the users and clients’ unique needs and analyze novel solutions that deliver a balanced approach for the program.

Values

>Architecture And All | All Is One

We value the crossroads of design, research and social good

Man Chi Loy a.k.a. armechan, is a Hong Kong artist. Graduated in UC Davis and lived in the US and Amsterdam before. He likes to find inspiration in the streets and strangers he encounters. He likes to explore the relationship between people and urban landscape in Hong Kong. His art is characterised by vibrant colours, intricate details, and a touch of fantasy.

Artwow Creative Company is an award-winning company with an extensive library of art patterns, created from well-meaning Chinese characters by artists Hikoko Ito and her late father Sun Chan, which have wide potential applications, and are perfect for high-end brands targeting the affluent consumers in the Mainland Chinese, Japanese, and the South-East Asian markets.

BeCandle founded in 2012, is a Hong Kong-based creative handcraft factory that produces high-quality fragranced products. Our team is committed to exceptional craftsmanship, creating each product with premium quality natural-based raw materials, in close partnership with top European fine fragrance houses. Our in-house creatives and perfume lab provide the flexibility you need to ensure your projects are completed on time and to the highest standard, giving us the capability and professionalism to exceed your expectations.Contact us today to learn how BeCandle can help you deliver end-to-end, tailor-made service.

We see design as a process of exploring new things. We break traditional frameworks by exploring the relationship between objects and bringing new design concepts.

We offer diverse design services, including brand strategy, visual design, product design, furniture design, participatory design, art installation design, community design, and design education. We have participated in various international design activities, such as Guangzhou Design Exhibition 2023, Milan Superstudio Show 2022, the Stockholm Furniture & Light Fair 2019, and London Design Fair 2019.

In addition to commercial design, we also wish to redefine the position of design in society by intervening design in our community and making our works more human-centered and responsive to current social needs through education and public engagement in the design process.

Established in 2010 by award-winning designer Aries Sin Mei-Yuk, MODEMENT is a Hong Kong/London-based fashion label that pioneers gender-neutral, sustainable and fluid fashion. The brand adopts a zero-waste approach to creation, with all garments made in Hong Kong/London from natural, sustainable materials. Since the first collection debuted at Hong Kong Fashion Week in 2013, MODEMENT has been showcased at Milan Fashion Week in 2017 and Paris Fashion Week in 2018.

Jesse Lee is an international award-winning fashion designer that creates circular fashion by orchestrating recycled materials innovative technology and playful craftsmanship. Jesse holds a MA in Menswear from the University of Westminster (London, UK) and a degree in Fashion from Kingston University (UK). In 2022, he won the International Talent Support Contest (ITS) Sportswear Award powered by Lotto Sport. Jesse was awarded the Redress Design Award 2020 All Star accolade for my collaboration with The R Collective and Levi's® for the ‘Denim Reimagined’ collection. Also, he won the Redress Design Award 2018 Second Prize Mentorship with Orsola de Castro, as well as the Hong Kong Best Prize the same year.

Studio RYTE (pronounced “right”) is a Hong Kong based design studio comprised of passionate, innovative and energetic architects and product designers. They navigate between spatial and object design while blending their boundary. The studio generates powerful designs through interdisciplinary conversations and collaborations, an operation mode. They pay attention to details, identify different potential materials, ways of fabrication as well as different spatial practices that could make a breakthrough in designs to create unique and desirable experiences.

At THE FABRICK LAB we are creating our own version of ‘The Big Bang Theory’ through textiles. We observe the changes in our universe to inform our design... ‘AI and Nature’, ‘Technology and Craft’, ‘Smart production and Handmade’; these are the extreme spectrums which we weave together, in order to map out the future of textile design. At THE FABRICK LAB, textiles are not limited to physical construction, it is the principle of textile making that helps us navigate new ways to design. We are dreamers, realising our concepts through materialisation. We are led by green thinking, engaged by science and stimulated by traditional heritage techniques and their history. As an industry catalyst we are set to expand the boundaries of modern textiles for the future, with a wide disciplinary application.

The Centre for Immunology & Infection (C2i) is the fruit of a long-standing partnership between the University of Hong Kong and the Institut Pasteur, using novel technology platforms for biomarker discovery and the development of new vaccine and therapeutic strategies to face public health challenges and make Hong Kong a global centre of excellence for precision medicine and innovative interventions targeting emerging infectious diseases.

An international team that leverages a highly multi-disciplinary expertise

1,000m2 facilities including state-of-the-art laboratories, an advanced insectarium unique in Hong Kong, and a dedicated research clinic established for cohort recruitment

The most advanced equipment and technics supporting cutting-edge research to push the boundaries and drive ground-breaking discoveries

Bring Hope and Health to our Next Generation

Pioneers the use of novel microbes as diagnostic markers and potential remedies for different diseases

Be a leading force in the development of Microbiome diagnostics and therapeutics

Utilise the unique in-house and expanding metagenomic datasets to identified novel microbes as non-invasive accurate biomarkers and developed proprietary machine-learning algorithms that can accurately predict disease risk

Hong Kong Science and Technology Parks Corporation (HKSTP) has for over 20 years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that supported over 10 unicorns and Hong Kong’s leading R&D hub with over 13,000 research professionals and over 1,300 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.

Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Our growing innovation ecosystem is built around our key locations of Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long. The three InnoParks are realising a vision of new industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of industry.

Through our infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong’s international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.

Lumiere [芦明] is a project that focuses on reducing investor risk and boosting audience engagement in the entertainment sector. The Lumiere Project is a ground-breaking initiative that combines blockchain technology, AI, and a multiverse approach to transform entertainment financing.

New Horizon Health – A vision to prevent and cure cancer through screening and early detection

The pioneer and leader in China’s cancer screening market

Synergistic screening portfolio focusing on high-incidence cancer types

Range of cancer screening products approved by NMPA and obtained CE mark

Inspiring a New State of Health

High-growth biotech company dedicated to providing the best health information for ALL

Innovative diagnostics for cancer and infectious diseases

Empower individuals with quality health knowledge for informed decision-making

Established in 1971, Sino Group is one of the leading property developers in Hong Kong. It comprises three listed companies, namely Sino Land Company Limited (HKSE: 0083), Tsim Sha Tsui Properties Limited (HKSE: 0247) and Sino Hotels (Holdings) Limited (HKSE: 1221), as well as private companies held by the Ng Family.

For more than half a century, we have been Creating Better Lifescapes, our vision of building a better life together, where the community thrives in harmony by embracing green living and wellness, by pursuing meaningful designs and seeking innovation while respecting heritage and serving the community.

The Group’s core business is developing residential, office, industrial and retail properties for sale and investment. It is complemented by a full range of property services encompassing management, security, car park operations and environmental services to ensure a seamless Sino Experience. We are also a key player in hotel and club management. In addition to an extensive portfolio in Hong Kong, the Group has footprint in Mainland China, Singapore and Australia. The Group has been involved in more than 250 projects, spanning a total plot ratio area of over 130 million sq ft.

The Group has a team that counts over 11,000 across the Asia Pacific, who share the mission of creating better lifescapes by delivering quality products and services while upholding integrity and advocating sustainability.

As a committed corporate citizen, Sino Group has been actively participating in community services and green activities as well as arts and culture events.

CITIC Capital Holdings Limited (""CITIC Capital"") is an alternative investment management and advisory company. The firm manages over USD18 billion of capital through its multi-asset class platform covering private equity, real estate, structured investment & finance, asset management, and special situations. CITIC Capital has over 160 portfolio companies that span 11 sectors and employ over 600,000 people around the world.

The firm combines a deep knowledge of the Chinese business and financial markets with world-class investment expertise to create and maximize value for its investors.

Established in 1987, the HKVCA's mission is to encourage a vibrant venture capital and private equity industry in Asia while promoting the role of member firms in value creation, innovation and economic development. The HKVCA provides a forum for networking and experience sharing for its members; promotes industry professional ethics, international best practices and standards; and represents the views of its members before governmental and other relevant bodies.

HKVCA represents over 520 corporate members, include 300 private equity firms across all types – including the 10 largest PE firms as well as small VC investors, managing a total of US$2 trillion in assets. These firms are engaged in venture capital and private equity investments in the Asia-Pacific region at all levels – from venture, growth, buyout, secondary, to pension, funds of fund, family offices, etc.

Oldham, Li & Nie (OLN) is a highly successful full-service law firm operating from Hong Kong and Shanghai with a commitment to professional excellence, tailoring its legal services to the needs of both corporate and private clients.

Founded in 1987 by Gordon Oldham, the firm currently has a total staff of over 100 with 43 qualified lawyers, admitted to one or more jurisdictions, including Hong Kong, France, the United Kingdom, the United States, Australia and Canada. OLN also has a thriving China practice, carried on from its Hong Kong and Shanghai offices and when necessary with its associate legal network in mainland China.

The French Practice at OLN, led by a lawyer registered with the Paris bar, has been advising entrepreneurs and corporations’ expansion in Hong Kong and Mainland China for many years. The French Practice builds on the firm’s know-how with a French angle, working with teams in other practice groups, including Corporate, Commercial and Intellectual Property Law.

OLN has a presence in Paris through its partnership with Ginestié Paley-Vincent. Its clients range from publicly listed companies, developers, banks, private companies and individuals, to different Government bodies.

The key business sectors advised are: Banking and Financial Services, International Trade, Private Equity, Energy, Food and Beverage and Hospitality, Consumer Products, Media and Information Technology.

There is an urgent need for safe and effective therapeutic options for COVID-19, with the SARS-CoV-2 variants associated with enhanced transmissibility and reduced vaccine-induced protection. Under this project, two orally administrated FDA approved over counter drugs, colloidal bismuth subcitrate and a mucoactive drug N-acetyl cysteine together is a safe and highly potent therapy through oral administration and 10 times more selective in killing the virus than the first FDA approved drug. This therapy is now in phase II/III clinical trial in Hong Kong, with a phase III trial underway in China.

Ecolar Tech Ltd. is a High-Tech company focusing on developing green antimicrobial materials and products that can keeping people’s health and protecting environment.

Gihon Biotech, established in 2016, is a green biopharmaceutical company launched to develop skin and health care products enriched in natural ingredients. Gihon Biotech has a professional R&D team comprising with experts from Hong Kong Baptist University including Professors, Post-doctors and PhD students. Our experienced R&D consultants have been working in the fields of plant medicine and natural products for more than 25 years. Our specialty ingredients are specialized to the formulation of products for skin protection and skin whitening whilst they are also applicable to the preparation of antiaging, antimicrobial and anti-inflammatory supplements.

HKCeND is committed to utilizing the innovative biotechnology for developing the diagnostic and therapeutic solutions for neurodegenerative diseases.

The Institute for Innovation, Translation and Policy Research (ITPR) strives to bridge the gap in technology readiness between academic innovation and industry applications. We advance Hong Kong Baptist University's(HKBU) innovation capacity and enhance up-to mid-stream research and technology development capabilities through establishing collaborative platforms, engaging stakeholders, facilitation high-impact innovation and multidisciplinary R&D

Maestroclin Limited is dedicated to discovering and characterizing novel metabolism-related factors, with the ultimate goal of understanding their mechanisms and applying them to real-life applications in the pharmaceutical industry. Leveraging our expertise in biological sample screening from various databases and state-of-the-art metabolic phenotyping platforms, we have successfully identified several new metabolic factors, including hormones and receptors, that exhibit great potential in the treatment of diabetes and fatty liver diseases. We are committed to actively exploring business opportunities with biotechnology and pharmaceutical companies for contract research, as well as for licensing or selling our pipelines.

PhoMedics is a MedTech startup that aims to revolutionize how cancer cells are detected before, during, and after cancer surgeries by developing cutting-edge imaging solutions for rapid, accurate, and on-the-spot histological imaging. We invented the CHAMP Microscope™, a breakthrough technology that provides highresolution, virtually stained images of fresh tissue within minutes, significantly enhancing surgical efficiency. With the integration of Deep-CHAMP, a deep learning algorithm, grayscale images are transformed into virtually stained H&E images with over 90% accuracy.
PhoMedics is dedicated to improving clinical workflow, offering a more reliable, faster, and label-free imaging solution, and setting new standards in medical diagnostics.

Founded in 1963, The Chinese University of Hong Kong(CUHK) is a forward-looking comprehensive research university with a global vision and a mission to combine combine tradition with modernity, and to bring together China and the West.

The Hong Kong Polytechnic University (PolyU) aspires to be an innovative world-class university with a strong sense of social responsibility. PolyU pursues impactful innovation and interdisciplinary research to address the world’s most pressing challenges. A robust culture of knowledge transfer and entrepreneurship is a cornerstone of the University, ensuring technologies are transformed into practical real-world applications. PolyU’s unwavering commitment to excellence has earned it international recognition, with consistent ranking among the top 100 universities worldwide. The University will continue to make positive contributions in collaboration with its strategic partners for the betterment of Hong Kong, the Nation, and the world.

Founded in 1911, The University of Hong Kong (HKU) is the first and oldest institution of higher education in Hong Kong. HKU has an established worldwide reputation for being a research-led comprehensive university and a strong commitment to intellectual freedom, liberty and diversity.
The Technology Transfer Office (TTO) manages the use of HKU’s intellectual property assets by providing patenting, licensing and other commercialisation support to the University’s researchers and inventors. Acting as the bridge linking HKU to society in the area of technology commercialisation, TTO helps industries and businesses access HKU’s powerhouse of knowledge, innovation and expertise through close collaboration.

Time Medical (TM) is an innovative leader in the medical imaging field and has developed advanced medical imaging systems, including MRI, DR and mobile diagnostic platform, to create cost-effective service solutions for emerging global healthcare needs. It has R&D centers and sales&marketing branches in Silicon Valley, Hong Kong, Shanghai and Singapore, and production facilities in China and India.

TM owns disruptive technologies in the medical imaging industry, including high-temperature superconducting (HTS) RF coil and magnet, ultrahigh field superconducting magnet and system, artificial intelligence imaging, dedicated MR systems, mobile diagnostic platform and tele-imaging service. It has a leading R&D team from Columbia University and Harvard Medical, with over 30 years of experience in the industry.

TM develops innovative 3B imaging systems for Baby (Neona), Breast (Emma) and Brain (Nova) care.

The world first Neonatal MRI won the """"Geneva Award"""" in Geneva Invention Convention. It is light, fast, accurate and safe, and could be installed in over 8,000 Neonatal Intensive Care Units (NICU) worldwide for precisive and non-radiative diagnosis of babies.

TM has developed dedicated MR for AI breast cancer screening to the breast diagnostic centers in the US and Asia. There are 8,600 breast mammography centers in the US with annual screening rate of 80% women aged over 45, while such rate is 1% in Asia. X-ray based mammography has radiation risk and a lower accurate rate of 60%, while MR has over 85% accuracy.

TM has developed ultra-high field preclinical MRI systems for biomed research market. These systems are used for the clinical research of neurologic functions and cancer diagnosis.

Thus far, TM has installed its products in more than 500 clinical centers in 15 countries. It is the No. 1 MRI player in the fast-growing private hospital market of Asia and has taken 40% market share in China Pet MRI market.

YnnoMed is a drug R&D platform committed to help those suffering from drug-resistant microbes by developing first-in-class antimicrobials with new modes-of-action. To improve the market situation that lacking of new drugs, we created this platform to lower the costs in drug discovery and development, reduce failure and increase the speed at which drugs are made available in clinical practice. Using in-house AI-assisted technology, YnnoMed has generated several series of antibiotic drug candidates with unprecedented protein targets, new chemical structures and unique antimicrobial mechanisms. Our most advanced pipelines show great promise for clinical use with the ability to kill resistant bacteria effectively, good drug efficacy in animal experiments, low cytotoxicity and low chance of inducing drug resistance. Working together with our global partners, we seek to turn the tide of antimicrobial resistance by marketising the first “made in Hong Kong” antibiotics and by inspiring other key players to embrace revolutionary approaches to enhance the global pipeline.